AAD 2026Abstract 73858
Novel Regulatory T-cell enhancing Biologic Rezpegaldesleukin
Phase 2b Efficacy, Safety, and Baseline Severity–Dependent Treatment Response in Moderate-to-Severe Atopic Dermatitis
Chaudhry S, Silverberg J, Rosmarin D, Chovatiya R, Bieber T, Warren R, Gooderham M, Gkalpakiotis S, Liu Y, Zalevsky J
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Atopic dermatitis & eczema
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1265 · Not in PubMed: details from Crossref